Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking
Study Details
Study Description
Brief Summary
This phase III trial compares the Quit2Heal smoking cessation smartphone application (app) to the QuitGuide app in helping cancer patients quit smoking. Both apps provide tools to cope with urges to smoke, step-by-step guides for quitting smoking, help in planning for quitting and staying tobacco-free, and scientifically-based recommendations for how to select medications that aid in smoking cessation.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive the Quit2Heal app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.
ARM II: Patients receive the QuitGuide app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.
After randomization, patients are followed up at 3, 6, and 12 months.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Arm I (Quit2Heal app) Patients receive the Quit2Heal app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it. |
Behavioral: Quit2Heal
Use Quit2Heal app
Other Names:
Other: Survey Administration
Ancillary studies
|
| Active Comparator: Arm II (QuitGuide app) Patients receive the QuitGuide app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it. |
Behavioral: QuitGuide
Use QuitGuide app
Other Names:
Other: Survey Administration
Ancillary studies
|
Outcome Measures
Primary Outcome Measures
- Number of participants with 30-day cigarette smoking cessation at 12 months. [At 12 months after randomization]
No smoking at all in the past 30 or more days.
Secondary Outcome Measures
- Number of participants with 30-day cigarette smoking cessation at 3 months. [At 3 months after randomization]
No smoking at all in the past 30 or more days.
- Number of participants with 30-day cigarette smoking cessation at 6 months. [At 6 months after randomization]
No smoking at all in the past 30 or more days.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosed with cancer within the past 12 months or currently receiving or planning to receive cancer treatment in the next 3 months
-
Smoked a cigarette (even a puff) in the past 30 days
-
Interested in learning skills to quit smoking
-
Willing to be randomly assigned to either smartphone application
-
Live in the United States and will remain in the United States (US) for the next 12 months
-
Have at least daily access to their own smartphone
-
Know how to download a smartphone application
-
Be willing and able to read English
-
Not currently (i.e., within past 30 days) using other smoking cessation interventions
-
Have never participated in our prior research trials
-
Have never used the National Cancer Institute (NCI)'s QuitGuide app
-
Being willing to complete a follow-up survey at 3, 6, and 12 months post-randomization
-
Providing email, phone number(s), and mailing address
Exclusion Criteria:
-
Currently (i.e., within past 30 days) using other smoking cessation interventions
-
Has participated in our prior research trials
-
Has used the NCI's QuitGuide app
-
Not willing to complete a follow-up survey at 3, 6, and 12 months post-randomization
-
Not providing email, phone number(s), and mailing address
-
Current use of Food and Drug Administration (FDA)-approved quit smoking medications: nicotine patch, nicotine gum, nicotine lozenge, nicotine nasal spray, nicotine inhaler, Chantix (varenicline), or Wellbutrin (Zyban/bupropion)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | United States | 98109 |
Sponsors and Collaborators
- Fred Hutchinson Cancer Center
- National Cancer Institute (NCI)
- American Cancer Society, Inc.
- Memorial Sloan Kettering Cancer Center
Investigators
- Principal Investigator: Jonathan Bricker, Fred Hutch/University of Washington Cancer Consortium
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RG1007577
- NCI-2020-03442
- 10432
- R01CA253975